How Common is Gastroparesis with GLP-1 Receptor Agonists?
Gastroparesis as a diagnosed adverse event is relatively uncommon with GLP-1 receptor agonists, occurring in approximately 5% of patients, though delayed gastric emptying (a related but distinct phenomenon) is substantially more prevalent and affects a much larger proportion of users.
Incidence of Diagnosed Gastroparesis
The most recent real-world evidence shows that diagnosed gastroparesis occurs in 5.1% of GLP-1 RA users 1. However, a large retrospective cohort study found an increased risk of gastroparesis with a hazard ratio of 1.591 compared to other oral antidiabetic medications 2. This represents a 59% increased relative risk, though the absolute incidence remains in the single digits.
Delayed Gastric Emptying vs. Clinical Gastroparesis
It's critical to distinguish between delayed gastric emptying (a physiologic effect) and clinical gastroparesis (a symptomatic diagnosis):
- Delayed gastric emptying is the mechanism of action of GLP-1 RAs and occurs in the majority of patients 3, 4
- Retained gastric contents have been documented in 24.2-56% of patients on GLP-1 RAs despite appropriate fasting, depending on the study population 4
- Clinical gastroparesis (symptomatic, diagnosed condition) occurs in only ~5% 1
Key Risk Factors for Gastroparesis
The evidence suggests certain populations are at higher risk:
- Patients with pre-existing diabetes appear to have different risk profiles than those using GLP-1 RAs solely for weight loss
- Duration of therapy matters: One study found all patients with gastric residue were on long-acting GLP-1 RAs with a median treatment duration of 57 months 4
- Recent initiation: Patients started on therapy within the preceding 4 weeks showed higher rates of retained gastric contents 4
Important Clinical Nuance
Guidelines explicitly state to avoid GLP-1 RAs in patients with pre-existing gastroparesis 4. However, one study found that exenatide treatment did not worsen gastric emptying in patients with pre-existing gastroparesis, with negative effects only detected in those without or with mild gastroparesis 5. This paradoxical finding suggests tachyphylaxis may occur in the gastric emptying effects over time.
Comparative Risk Between Agents
Among GLP-1 RAs, dulaglutide and liraglutide had higher odds of gastroparesis compared to semaglutide 1. Exenatide appeared to have a more favorable profile for most GI adverse events except gastroparesis 1.
Common Pitfalls
- Don't confuse delayed gastric emptying with gastroparesis: The former is expected pharmacology; the latter is a clinical diagnosis
- Nausea and vomiting are dose-dependent and occur in 23.4% of patients 1, but these symptoms don't necessarily indicate gastroparesis
- The peri-operative implications are distinct: Up to 56% of patients may have retained gastric contents despite fasting 4, creating aspiration risk even without diagnosed gastroparesis
Bottom Line for Clinical Practice
While diagnosed gastroparesis affects only ~5% of GLP-1 RA users, the broader issue of delayed gastric emptying affects the majority. Screen patients for pre-existing gastroparesis before initiating therapy, use slow titration to minimize GI symptoms, and maintain heightened awareness in the peri-operative setting where delayed gastric emptying poses aspiration risk regardless of whether clinical gastroparesis is present.